Three Months Treatment With SB683699 In Patients With Relapsing Multiple Sclerosis [clinicaltrials:NCT00097331]

Bio2RDF uri

Three Months Treatment With SB683699 In Patients With Relapsing Multiple Sclerosis [clinicaltrials:NCT00097331]

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

http://bio2rdf.org/clinicaltrials:NCT00097331

Bio2RDF identifier

NCT00097331

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT00097331

http://www.w3.org/2001/XMLSchema#string

identifiers.org URI

NCT00097331

actual enrollment [clinicaltrials_vocabulary:actual-enrollment]

261

http://www.w3.org/2001/XMLSchema#integer

authority [clinicaltrials_vocabulary:authority]

clinicaltrials_resource:6e257bf0e085fce2334a6b0be6d217fe

brief summary [clinicaltrials_vocabulary:brief-summary]

The study will evaluate ...... I) scans as the main measure.

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

Three Months Treatment With SB683699 In Patients With Relapsing Multiple Sclerosis

http://www.w3.org/2001/XMLSchema#string

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

Number of new gadolinium-enhancing lesions on monthly MRI scans [clinicaltrials_resource:7969f3a605efe849bc594ccc44e35a89]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

Number of new gadolinium-enhancing lesions on monthly MRI scans [clinicaltrials_resource:2e6a5ecacf45a51ff6447075471f03e1]

Number of new gadolinium-enhancing lesions on monthly MRI scans [clinicaltrials_resource:7ac19cb1f64073b56308ee0f3f32a48d]

Number of new gadolinium-enhancing lesions on monthly MRI scans [clinicaltrials_resource:c1bc7824234195f26e246bf87c8b1506]

Number of new gadolinium-enhancing lesions on monthly MRI scans [clinicaltrials_resource:d57ff59b6e0189a52c2f0fc3edb54504]

Number of new gadolinium-enhancing lesions on monthly MRI scans [clinicaltrials_resource:fa69c31a45fd0ba102c09f7af970f3cf]

completion date [clinicaltrials_vocabulary:completion-date]

2006-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT00097331 [clinicaltrials_resource:76623e93d9c349e030b73777ba6c6b5e]

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2004-11-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

http://www.w3.org/2001/XMLSchema#string

intervention [clinicaltrials_vocabulary:intervention]

SB683699 [clinicaltrials_resource:a65334cb0cd4c3c8cd38fd717a75b4b5]

keyword [clinicaltrials_vocabulary:keyword]

Relapsing-Remitting MS (RRMS)

http://www.w3.org/2001/XMLSchema#string

multiple sclerosis

http://www.w3.org/2001/XMLSchema#string

relapsing

http://www.w3.org/2001/XMLSchema#string

remitting

http://www.w3.org/2001/XMLSchema#string

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2015-04-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

GlaxoSmithKline [clinicaltrials_resource:8075d9d563cbe75004e7b6c2c4360b29]

location [clinicaltrials_vocabulary:location]

GSK Investigational Site [clinicaltrials_resource:a3353581a873f7d7c72281af6202cb5c]

nct id [clinicaltrials_vocabulary:nct-id]

NCT00097331

http://www.w3.org/2001/XMLSchema#string

official title [clinicaltrials_vocabulary:official-title]

A Randomised, Double-blind, Pl ...... h Relapsing Multiple Sclerosis

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

683699/003

http://www.w3.org/2001/XMLSchema#string

overall official [clinicaltrials_vocabulary:overall-official]

GSK Clinical Trials [clinicaltrials_resource:482ca15ed5613e7d70d0185ac9204ca5]

overall status [clinicaltrials_vocabulary:overall-status]

Completed [clinicaltrials_resource:07ca5050e697392c9ed47e6453f1453f]

oversight [clinicaltrials_vocabulary:oversight]

Germany: Federal Institute for Drugs and Medical Devices [clinicaltrials_resource:2edde799419e819ade27184d926609b1]

phase [clinicaltrials_vocabulary:phase]

Phase 2 [clinicaltrials_resource:56e0338b27a2d68f77402c88327b3f8d]

primary completion date [clinicaltrials_vocabulary:primary-completion-date]

2006-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

responsible party [clinicaltrials_vocabulary:responsible-party]

[clinicaltrials_resource:dbd41868ee618d3e64daa1adf8c3a8a0]

source [clinicaltrials_vocabulary:source]

GlaxoSmithKline [clinicaltrials_resource:8075d9d563cbe75004e7b6c2c4360b29]

start date [clinicaltrials_vocabulary:start-date]

2004-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT00097331 study design [clinicaltrials_resource:4f8fc4dd67ae5034e57c893f3d6e6e52]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT00097331

verification date [clinicaltrials_vocabulary:verification-date]

2015-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT00097331

http://www.w3.org/2001/XMLSchema#string

title

Three Months Treatment With SB683699 In Patients With Relapsing Multiple Sclerosis

@en

inDataset

clinicaltrials_resource:bio2rdf.dataset.clinicaltrials.R3

type

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

label

Three Months Treatment With SB ...... s [clinicaltrials:NCT00097331]

@en